Bordetella Bronchiseptica Vaccine, Avirulent Live Culture

Verify with FDA CVM →

633 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
633
Total Reports
43
Deaths Reported
680.0%
Death Rate

Active Ingredients

Bordetella Bronchiseptica Vaccine, Avirulent Live Culture

Administration Routes

OralUnknownSubcutaneousBuccalParenteralNasalTopicalOther

Species Affected

Dog 633

Most Affected Breeds

Retriever - Labrador 98
Retriever - Golden 53
Shepherd Dog - Australian 32
Chihuahua 27
Shih Tzu 26
Terrier - Yorkshire 22
Pug 15
Dachshund (unspecified) 15
Shepherd Dog - German 15
Boxer (German Boxer) 14

Most Reported Reactions

Vomiting 147
Lack of efficacy - NOS 76
Lack of efficacy (virus NOS) 71
Other abnormal test result NOS 61
Cough 55
Diarrhoea 49
Lethargy (see also Central nervous system depression in 'Neurological') 47
Lack of efficacy (virus) - NOS 44
Lethargy (see also Central nervous system depression in Neurological) 41
Facial swelling (see also 'Skin') 32
Anaphylaxis 29
Not eating 28

Outcome Breakdown

Outcome Unknown
322 (50.8%)
Recovered/Normal
184 (29.0%)
Ongoing
84 (13.2%)
Died
24 (3.8%)
Euthanized
19 (3.0%)
Recovered with Sequela
1 (0.2%)

Data Summary

Metric Value
Total adverse event reports 633
Reports involving death 43
Case-fatality rate (reported events) 680.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Bordetella Bronchiseptica Vaccine, Avirulent Live Culture Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 633 adverse event reports referencing Bordetella Bronchiseptica Vaccine, Avirulent Live Culture, including 43 reports in which the animal died — a 680.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Bordetella Bronchiseptica Vaccine, Avirulent Live Culture. Reported administration routes include Oral, Unknown, Subcutaneous, Buccal. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Bordetella Bronchiseptica Vaccine, Avirulent Live Culture reports are Dog (633 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (98), Retriever - Golden (53), Shepherd Dog - Australian (32) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Bordetella Bronchiseptica Vaccine, Avirulent Live Culture are Vomiting (147), Lack of efficacy - NOS (76), Lack of efficacy (virus NOS) (71), Other abnormal test result NOS (61). Of the 634 reports with a coded outcome, Outcome Unknown is the leading category at 50.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Bordetella Bronchiseptica Vaccine, Avirulent Live Culture.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial